Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer
Summary: Although PD-1-blocking immunotherapies demonstrate significant therapeutic promise, a subset of the patients could develop hyperprogressive disease (HPD) with accelerated tumor growth after anti-PD1 immunotherapy. To elucidate the underlying mechanisms, we compared the mutational and transc...
Main Authors: | Donghai Xiong, Yian Wang, Arun K. Singavi, Alexander C. Mackinnon, Ben George, Ming You |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-11-01
|
Series: | iScience |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004218301809 |
Similar Items
-
Hyperprogression under Immunotherapy
by: Maxime Frelaut, et al.
Published: (2019-05-01) -
Hyperprogression after Immunotherapy: Nivolumab. Analysis of Imaging Findings Associated with Hyperprogression and Tumor Growth Kinetics
by: Rishu Singla, et al.
Published: (2021-04-01) -
Is hyperprogressive disease a specific phenomenom of immunotherapy?
by: Marta Brambilla, et al.
Published: (2020-12-01) -
Hyperprogression: A novel response pattern under immunotherapy
by: Xue‐jiao Han, et al.
Published: (2020-09-01) -
Hyperprogression after immunotherapy in patients with malignant tumors of digestive system
by: Zhi Ji, et al.
Published: (2019-07-01)